BAW enables surface-based mass measurement. Qorvo’s BAW technology uses high frequency and surface binding that, based on results of early stage feasibility studies, suggests the potential for sensitivity and variance control similar to central labs. These two factors have limited the ubiquitous deployment of point-of-care solutions based on historical optical or fluorescence detection systems. The innovation is uniquely positioned to allow for the dual testing capability of Molecular and Immunoassays on the same cartridge and instrument interface. Beyond this, BAW allows for multiplexing (multiple analytes tested off a single sample), and the cartridge has been designed to allow measurements of multiple matrix types including whole blood, serum, plasma, saliva and more. The goal is to enable clinicians’ access to point-of-care test data in minutes.